Forsta AP Fonden purchased a new position in shares of Solventum Co. (NYSE:SOLV - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 28,400 shares of the company's stock, valued at approximately $1,876,000.
Several other hedge funds have also recently made changes to their positions in SOLV. Copeland Capital Management LLC acquired a new position in shares of Solventum during the third quarter valued at about $26,000. Modus Advisors LLC bought a new stake in Solventum in the 4th quarter valued at about $25,000. Mather Group LLC. acquired a new position in Solventum during the 3rd quarter worth approximately $27,000. True Wealth Design LLC boosted its holdings in Solventum by 23,550.0% in the third quarter. True Wealth Design LLC now owns 473 shares of the company's stock worth $33,000 after acquiring an additional 471 shares in the last quarter. Finally, Prospera Private Wealth LLC acquired a new stake in Solventum in the third quarter valued at approximately $35,000.
Analyst Ratings Changes
A number of equities analysts have recently weighed in on the company. Morgan Stanley upped their target price on Solventum from $60.00 to $73.00 and gave the stock an "equal weight" rating in a research report on Monday, November 11th. Piper Sandler upped their price objective on shares of Solventum from $71.00 to $75.00 and gave the stock a "neutral" rating in a report on Friday, November 8th. Finally, Mizuho began coverage on shares of Solventum in a research note on Wednesday, December 4th. They issued a "neutral" rating and a $70.00 price objective on the stock. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Solventum currently has an average rating of "Hold" and an average target price of $68.29.
Read Our Latest Stock Report on SOLV
Solventum Stock Performance
Shares of NYSE SOLV traded down $0.06 during trading on Thursday, hitting $74.73. The stock had a trading volume of 934,529 shares, compared to its average volume of 975,097. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $96.05. The firm has a fifty day moving average of $70.32 and a two-hundred day moving average of $67.76. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.
Solventum (NYSE:SOLV - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.15 EPS for the quarter, missing analysts' consensus estimates of $1.38 by ($0.23). The company had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.05 billion. As a group, sell-side analysts anticipate that Solventum Co. will post 6.58 EPS for the current fiscal year.
About Solventum
(
Free Report)
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Recommended Stories
Before you consider Solventum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.
While Solventum currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
